Core Insights - The company reported a revenue of 50.961 million, representing a year-on-year increase of 703.8% [1] - Gross profit reached 29.369 million, showing a significant year-on-year growth of approximately 1716% [1] - The net loss narrowed to 75.483 million, a reduction of 78.53% compared to the previous year [1] - The loss per share was recorded at 0.14 yuan [1] Financial Performance - Revenue: 50.961 million, up 703.8% year-on-year [1] - Gross Profit: 29.369 million, up approximately 1716% year-on-year [1] - Net Loss: 75.483 million, down 78.53% year-on-year [1] - Loss per Share: 0.14 yuan [1] Factors Influencing Performance - The reduction in loss was primarily attributed to decreased R&D expenses, lower administrative costs, an increase in net foreign exchange gains, and higher gross profit [1]

Core Insights - The company reported a significant increase in revenue for the first half of 2025, amounting to 50.96 million yuan, representing a year-on-year growth of 703.8% [1] - Gross profit reached 29.37 million yuan, showing an impressive year-on-year increase of approximately 1,716% [1] - The net loss narrowed to 75.48 million yuan, a reduction of 78.53% compared to the previous year, with a loss per share of 0.14 yuan [1] Financial Performance - Revenue: 50.96 million yuan, up 703.8% year-on-year [1] - Gross Profit: 29.37 million yuan, up approximately 1,716% year-on-year [1] - Net Loss: 75.48 million yuan, down 78.53% year-on-year [1] - Loss per Share: 0.14 yuan [1] Contributing Factors - The reduction in losses was primarily attributed to decreased R&D expenses, lower administrative costs, an increase in net foreign exchange gains, and a rise in gross profit [1]

Performance Highlights [Financial Highlights](index=1&type=section&id=Financial%20Highlights) For the six months ended June 30, 2025, the company significantly improved its financial position, with revenue of RMB 51 million, gross profit of RMB 29 million, and a narrowed net loss of RMB 75 million, supported by strong cash reserves Key Financial Indicators for the Six Months Ended June 30, 2025 | Metric | H1 2025 (Million RMB) | H1 2024 (Million RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | Approx. 51 | Approx. 6.3 | +704% | | Gross Profit | Approx. 29 | Approx. 1.6 | +1712% | | Net Loss | Approx. 75 | Approx. 352 | Loss narrowed by 78.7% | | Adjusted Net Loss | Approx. 72 | Approx. 342 | Loss narrowed by 79.0% | | Cash and Bank Balances at Period-End | Approx. 1,261 | - | - | - The significant reduction in net loss was primarily due to: (i) increased net other income; (ii) a **RMB 116 million** decrease in R&D expenses; (iii) a **RMB 47 million** decrease in administrative expenses; and (iv) increased gross profit[5](index=5&type=chunk) - As of June 30, 2025, cash and bank balances were approximately **RMB 1.261 billion**, with existing funds projected to support operations until 2028[7](index=7&type=chunk) [Business Highlights](index=3&type=section&id=Business%20Highlights) The company achieved significant business progress, with successful commercialization of core product CT053, NDA acceptance for CT041, and active advancement of differentiated allogeneic CAR-T pipelines using proprietary platforms - Commercialization of **CT053 (Zevor-cel)** in mainland China, in collaboration with Huadong Medicine, progressed smoothly, securing **111 valid orders** in H1 2025[9](index=9&type=chunk) - The New Drug Application (NDA) for **CT041 (Sure-cel)** for advanced gastric cancer was accepted by China's NMPA, granted priority review, and designated as a breakthrough therapy[10](index=10&type=chunk) - The company is advancing multiple allogeneic CAR-T cell products, including CT0596, using its proprietary THANK-uCAR® and upgraded THANK-u Plus™ platforms to overcome limitations of existing therapies[11](index=11&type=chunk) Business Review and Outlook [Company Overview and Strategy](index=4&type=section&id=Company%20Overview%20and%20Strategy) Coherent Biopharma is a biopharmaceutical company focused on innovative CAR-T cell therapies with end-to-end capabilities, strategically optimizing its pipeline for differentiated clinical and commercial value while expanding into the US market - The company is positioned as a biopharmaceutical firm dedicated to developing innovative CAR-T cell therapies addressing unmet clinical needs in hematological malignancies, solid tumors, and autoimmune diseases[12](index=12&type=chunk) - The company's strategy focuses on developing breakthrough CAR-T products, regularly evaluating its pipeline for differentiated projects, and actively integrating resources to advance its US market strategy[13](index=13&type=chunk) [Product Pipeline Review](index=4&type=section&id=Product%20Pipeline%20Review) The company boasts a rich product pipeline, including commercialized CT053, NDA-accepted CT041, and multiple clinical and preclinical candidates targeting novel antigens and allogeneic CAR-T, demonstrating robust R&D innovation Key Product Pipeline Progress | Candidate Product | Target | Primary Indication | Latest Progress | | :--- | :--- | :--- | :--- | | **Zevor-cel (CT053)** | BCMA | Relapsed/Refractory Multiple Myeloma | Commercialized in China | | **Sure-cel (CT041)** | Claudin18.2 | Gastric Cancer/GEJ Adenocarcinoma | NDA accepted in China | | **CT071** | GPRC5D | Relapsed/Refractory Multiple Myeloma | Phase I clinical, ORR data 100% | | **CT011** | GPC3 | Hepatocellular Carcinoma | NMPA IND approved | | **Allogeneic CAR-T** | BCMA, CD19/20, etc. | Multiple Myeloma, B-cell Lymphoma, etc. | Multiple products in IIT stage, CT0596 showing positive preliminary efficacy | [Zevor-cel (CT053) - BCMA CAR-T](index=5&type=section&id=Zevor-cel%20(CT053)%20-%20BCMA%20CAR-T) Zevor-cel (CT053), an NMPA-approved all-human BCMA CAR-T product, is commercializing well in China with 111 orders in H1 2025 and showed a 92.2% ORR in LUMMICAR-1, though its US/Canada LUMMICAR-2 study priority has been strategically reduced - In collaboration with Huadong Medicine for commercialization in mainland China, Coherent Biopharma is eligible for up to **RMB 1.025 billion** in regulatory and sales milestone payments, having secured **111 valid orders** in H1 2025[17](index=17&type=chunk) - LUMMICAR-1 study data showed an **Overall Response Rate (ORR) of 92.2%** and a **stringent Complete Response (sCR)/Complete Response (CR) rate of 71.6%** in 102 patients[20](index=20&type=chunk) - As part of a strategic adjustment, the company decided to de-prioritize the LUMMICAR-2 study for Zevor-cel in the US and Canada[21](index=21&type=chunk) [Sure-cel (CT041) - Claudin18.2 CAR-T](index=6&type=section&id=Sure-cel%20(CT041)%20-%20Claudin18.2%20CAR-T) Sure-cel (CT041), a potential global first-in-class Claudin18.2 CAR-T, received NMPA NDA acceptance, priority review, and breakthrough therapy designation in June 2025 for advanced gastric/GEJ adenocarcinoma, demonstrating significant PFS/OS improvement and manageable safety in a confirmatory Phase II trial - In June 2025, the NDA for Sure-cel was accepted by China's NMPA for Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma patients who failed at least two prior lines of therapy[23](index=23&type=chunk) - Confirmatory Phase II clinical trial (CT041-ST-01) data showed a **median Overall Survival (mOS) of 9.17 months** for Sure-cel-treated patients, compared to only **3.98 months** for the control group[24](index=24&type=chunk) - The company is actively exploring the product's application in earlier cancer treatment and perioperative settings, including adjuvant therapy for pancreatic cancer and post-gastrectomy consolidation therapy for gastric cancer[25](index=25&type=chunk) [CT011 - GPC3 CAR-T](index=8&type=section&id=CT011%20-%20GPC3%20CAR-T) CT011, an autologous GPC3-targeted CAR-T product for hepatocellular carcinoma (HCC), received NMPA IND approval in January 2024 for adjuvant therapy in GPC3-positive Stage IIIa HCC patients at risk of recurrence post-surgery, building on the founder's pioneering work - CT011 is an autologous GPC3-targeted CAR-T product for the treatment of hepatocellular carcinoma (HCC)[30](index=30&type=chunk) - In January 2024, CT011 received NMPA IND approval for adjuvant therapy in GPC3-positive Stage IIIa HCC patients at risk of recurrence after surgical resection[30](index=30&type=chunk) [CT071 - GPRC5D CAR-T](index=9&type=section&id=CT071%20-%20GPRC5D%20CAR-T) CT071, an autologous GPRC5D-targeted CAR-T developed with the CARcelerate® platform to reduce manufacturing time to 30 hours, demonstrated a **100% ORR** and **70% sCR** in a Phase I investigator-initiated trial for newly diagnosed multiple myeloma, highlighting its significant therapeutic potential - CT071, developed using the proprietary CARcelerate® platform, reduces manufacturing time to approximately **30 hours**, yielding younger and more potent CAR-T cells[32](index=32&type=chunk) - In a Phase I study for high-risk newly diagnosed multiple myeloma, CT071 achieved a **100% Overall Response Rate (ORR)**, with **70% of patients achieving stringent Complete Response (sCR)**[32](index=32&type=chunk) [Allogeneic CAR-T Cell Products](index=9&type=section&id=Allogeneic%20CAR-T%20Cell%20Products) Leveraging its proprietary THANK-uCAR® and upgraded THANK-u Plus™ platforms, the company is aggressively advancing its allogeneic CAR-T pipeline, with BCMA-targeted CT0596 showing encouraging efficacy and safety in R/R MM, and a dedicated subsidiary, Youkai-cel, established for R&D and commercialization of multiple allogeneic products - The company developed the THANK-u Plus™ platform as an upgrade to THANK-uCAR® technology, aiming to overcome the potential impact of NKG2A expression levels on allogeneic CAR-T efficacy[34](index=34&type=chunk) - In a preliminary clinical study of allogeneic product CT0596 for R/R MM, **3 out of 5 (60%)** patients who completed initial efficacy assessment achieved sCR/CR, **4 (80%)** achieved MRD negativity, with good safety[36](index=36&type=chunk) - The company established Youkai-cel, a subsidiary, and secured **RMB 80 million** in external investment, focusing on the R&D, manufacturing, and commercialization of allogeneic CAR-T cell therapies in China[38](index=38&type=chunk) [Technology Platforms and Innovation](index=11&type=section&id=Technology%20Platforms%20and%20Innovation) The company addresses CAR-T challenges through innovative platforms: THANK-uCAR®/THANK-u Plus™ for effective allogeneic CAR-T, CARcelerate® for 30-hour manufacturing, and CycloCAR®/LADAR™ for enhanced solid tumor efficacy and improved target availability/safety, holding over 300 patents Core Technology Platforms | Technology Platform | Goals and Advantages | | :--- | :--- | | **THANK-uCAR® / THANK-u Plus™** | Develop allogeneic CAR-T, improve patient accessibility, enhance cell expansion and persistence | | **CARcelerate®** | Reduce CAR-T cell manufacturing time to approximately 30 hours, improving production efficiency and cell potency | | **CycloCAR®** | Co-express IL-7 and CCL21, enhance efficacy against solid tumors, reduce lymphodepletion requirements | | **LADAR™** | Precisely control CAR-T cell activation through dual-antigen recognition, enhance safety, and address target availability challenges | - As of June 30, 2025, the company holds over **300 patents**, including **140 globally authorized patents**, demonstrating a robust intellectual property portfolio[44](index=44&type=chunk) [Manufacturing Capabilities](index=14&type=section&id=Manufacturing%20Capabilities) The company has established vertically integrated GMP manufacturing capabilities for plasmids, lentiviral vectors, and CAR-T cell products, supporting clinical trials and commercialization, with its Shanghai Jinshan plant serving China and the US RTP facility cleared by FDA for overseas clinical trials - The company has established vertically integrated CAR-T manufacturing capabilities, encompassing plasmids, lentiviral vectors, and CAR-T cell products, enhancing efficiency, control, and cost reduction[46](index=46&type=chunk) - The Shanghai Jinshan facility supports the commercial production of Zevor-cel and prepares for the commercialization of Sure-cel[46](index=46&type=chunk) - The RTP manufacturing facility in North Carolina, USA, passed an FDA re-inspection with zero deficiencies in September 2024, leading to the lifting of clinical hold on three trials by the FDA in October of the same year[47](index=47&type=chunk) [Market Outlook and Future Prospects](index=15&type=section&id=Market%20Outlook%20and%20Future%20Prospects) The global CAR-T market shows strong growth, with significant unmet needs in solid tumors; the company aims to advance core products into earlier treatment, develop innovative technologies, expand manufacturing, and seek collaborations to maximize value - The global CAR-T market is experiencing strong growth, yet significant unmet needs persist in solid tumor treatment, presenting development opportunities for the company[48](index=48&type=chunk) - The company's future focus includes: 1) advancing core products into earlier treatment; 2) developing other clinical and preclinical products; 3) continuously innovating CAR-T technologies; 4) expanding US and China manufacturing capabilities; and 5) establishing more external collaborations[49](index=49&type=chunk) Financial Review [Operating Performance Analysis](index=16&type=section&id=Operating%20Performance%20Analysis) During the reporting period, the company's operating loss significantly narrowed from RMB 362 million to RMB 77 million, with net loss decreasing by RMB 277 million to RMB 75 million, primarily due to controlled expenses, increased foreign exchange gains, and higher gross profit Operating Loss and Net Loss | Metric | H1 2025 (Million RMB) | H1 2024 (Million RMB) | | :--- | :--- | :--- | | Operating Loss | 77 | 362 | | Net Loss | 75 | 352 | - The reduction in loss was primarily attributed to decreased R&D expenses, reduced administrative expenses, increased net foreign exchange gains, and higher gross profit[51](index=51&type=chunk) [Non-IFRS Measures](index=16&type=section&id=Non-IFRS%20Measures) To better assess core business performance, the company reported Non-IFRS measures, with adjusted net loss for the six months ended June 30, 2025, significantly narrowing to RMB 71.8 million from RMB 342 million after excluding non-cash items like share-based compensation Reconciliation of Net Loss to Adjusted Net Loss (RMB Thousand) | Item | H1 2025 (Unaudited) | H1 2024 (Unaudited) | | :--- | :--- | :--- | | Loss for the period | (75,483) | (351,558) | | Add: Share-based payment expenses | 3,684 | 9,190 | | **Adjusted Net Loss** | **(71,799)** | **(342,368)** | [Analysis of Key Financial Items](index=17&type=section&id=Analysis%20of%20Key%20Financial%20Items) During the period, the company effectively controlled expenses, with revenue growing over 7-fold to RMB 50.96 million, R&D expenses decreasing by **47%** to RMB 130 million, and administrative expenses by **54%** to RMB 39 million, primarily due to lower staff costs, professional fees, and depreciation - R&D expenses decreased by **47%** from **RMB 246 million** to **RMB 130 million**, primarily due to reduced employee benefit expenses, testing and clinical expenses, and depreciation of property, plant, and equipment[58](index=58&type=chunk) - Administrative expenses decreased by **54%** from **RMB 86 million** to **RMB 39 million**, mainly due to reduced employee benefit expenses, professional service fees, and depreciation of property, plant, and equipment[59](index=59&type=chunk)[60](index=60&type=chunk) - Total employee benefit expenses decreased from **RMB 154 million** to **RMB 89.79 million**, primarily due to a reduction in headcount and lower remuneration[60](index=60&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held RMB 1.261 billion in cash and bank balances, with improved net cash outflow from operating activities of RMB 196 million and a net outflow of RMB 30 million from financing activities, resulting in zero total borrowings and a reduced liability ratio of **7.2%**, indicating a more robust financial structure Condensed Cash Flow Statement (RMB Thousand) | Item | H1 2025 (Unaudited) | H1 2024 (Unaudited) | | :--- | :--- | :--- | | Net cash used in operating activities | (196,308) | (255,947) | | Net cash generated from investing activities | 1,715 | 6,584 | | Net cash (used in)/generated from financing activities | (29,635) | 24,688 | | **Cash and cash equivalents at period-end** | **1,260,793** | **1,652,569** | - As of June 30, 2025, the Group's total borrowings decreased to **zero**, and the liability ratio (sum of borrowings and lease liabilities/total equity) decreased from **15.75%** at the end of 2024 to **7.2%**[69](index=69&type=chunk) - As of June 30, 2025, the company's total headcount was **371**, a reduction from **468** at the end of 2024[78](index=78&type=chunk) Supplemental Announcement Regarding 2024 Annual Report [Impairment Background and Reasons](index=24&type=section&id=Impairment%20Background%20and%20Reasons) This supplemental announcement clarifies asset impairments in the 2024 annual report, stemming from a strategic shift to allogeneic CAR-T pipelines due to strong data and competitive changes, reallocating resources from certain autologous pipelines lacking clear commercialization plans - For the year ended December 31, 2024, the company recorded an impairment of **RMB 162.3 million** for property, plant, and equipment, **RMB 26.5 million** for right-of-use assets, and **RMB 0.3 million** for intangible assets[81](index=81&type=chunk) - The primary reason for impairment was a strategic shift: due to excellent allogeneic CAR-T data, the company decided to reallocate resources from certain autologous CAR-T pipelines to allogeneic pipelines[82](index=82&type=chunk)[83](index=83&type=chunk) [Key Assumptions and Impairment Testing](index=24&type=section&id=Key%20Assumptions%20and%20Impairment%20Testing) The company conducted impairment tests on long-term assets based on strategic adjustments, using the Value in Use (VIU) method for autologous pipeline assets without clear commercialization plans, and fully impairing assets solely dedicated to these pipelines due to zero expected future cash inflows - Key impairment testing assumptions included reduced resource allocation to autologous pipelines without clear commercialization plans, and no definite commercialization plans for other autologous pipelines beyond those already marketed or in NDA stage[83](index=83&type=chunk) - The company used the Value in Use (VIU) method for impairment testing, with assets solely dedicated to de-prioritized autologous pipelines assigned a **zero VIU**, leading to a full impairment provision[84](index=84&type=chunk)[85](index=85&type=chunk) Condensed Consolidated Financial Statements [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=26&type=section&id=Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2025, the company reported a gross profit of RMB 29.37 million, a significantly narrowed operating loss of RMB 76.70 million from RMB 362 million, and a net loss of RMB 75.48 million, representing a **78.5%** year-over-year reduction, with basic loss per share at **RMB 0.14** Condensed Interim Consolidated Statement of Profit or Loss Summary (RMB Thousand) | Item | H1 2025 (Unaudited) | H1 2024 (Unaudited) | | :--- | :--- | :--- | | Revenue | 50,961 | 6,340 | | Gross Profit | 29,369 | 1,617 | | Operating Loss | (76,704) | (361,540) | | Loss before income tax | (75,483) | (351,558) | | **Loss for the period attributable to owners of the parent** | **(75,483)** | **(351,558)** | | Basic and diluted loss per share (RMB) | (0.14) | (0.63) | [Consolidated Statement of Financial Position](index=27&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the company reported total assets of RMB 1.513 billion, total liabilities of RMB 551 million, and net assets of RMB 962 million, with strong liquidity from RMB 1.380 billion in current assets, including RMB 1.261 billion in cash and bank balances, and an optimized balance sheet with zero interest-bearing bank borrowings Condensed Interim Consolidated Statement of Financial Position Summary (RMB Thousand) | Item | As of June 30, 2025 (Unaudited) | As of December 31, 2024 (Audited) | | :--- | :--- | :--- | | Total non-current assets | 133,498 | 142,759 | | Total current assets | 1,379,893 | 1,530,275 | | **Total Assets** | **1,513,391** | **1,673,034** | | Total current liabilities | 213,799 | 254,007 | | Total non-current liabilities | 337,459 | 362,320 | | **Total Liabilities** | **551,258** | **616,327** | | **Net Assets** | **962,133** | **1,056,707** | | Total Equity | 962,133 | 1,056,707 | Corporate Governance and Other Information [Dividends and Securities Transactions](index=36&type=section&id=Dividends%20and%20Securities%20Transactions) The Board recommends no interim dividend for the six months ended June 30, 2025, with no purchases, sales, or redemptions of listed securities by the company or its subsidiaries during the period, and all directors confirmed compliance with the adopted standard code - The Board recommends no interim dividend for the reporting period[116](index=116&type=chunk) - During the reporting period, neither the company nor its subsidiaries acquired, disposed of, or redeemed any of the company's listed securities[117](index=117&type=chunk) [Use of Proceeds from Global Offering](index=37&type=section&id=Use%20of%20Proceeds%20from%20Global%20Offering) The company, listed in June 2021, utilized approximately RMB 2.497 billion of its HKD 3.008 billion net global offering proceeds by June 30, 2025, primarily for CT053 development, pipeline R&D, and manufacturing, with the remaining balance expected to be fully used by 2026 Use of Proceeds from Global Offering (As of June 30, 2025) | Use of Proceeds | Planned Allocation (Million RMB) | Amount Utilized (Million RMB) | Balance (Million RMB) | | :--- | :--- | :--- | :--- | | Development of core product BCMA CAR-T (CT053) | 851.7 | 851.7 | 0 | | R&D for other pipelines | 849.9 | 759.6 | 90.3 | | Manufacturing and commercialization capabilities | 548.3 | 415.2 | 133.1 | | Technology upgrades and early-stage R&D | 274.1 | 214.7 | 59.4 | | Working capital and others | 255.5 | 255.5 | 0 | | **Total** | **2,779.5** | **2,496.7** | **282.8** | - The unutilized portion of the net proceeds is expected to be fully used for its intended purposes by 2026[124](index=124&type=chunk)

Group 1 - The investment bank maintains a cautiously optimistic view on the Chinese pharmaceutical industry, noting a 137% average increase in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals [1] - Recent pullbacks in the industry are attributed to disappointing sales figures from major biotech companies and concerns over potential phased drug tariffs proposed by Trump, which could reach 150% within a year and ultimately 250% [1] - The bank's preferred focus is on innovative sectors with strong performance in the first half of 2025, highlighting BeiGene (06160) with a target price of HKD 230 and a rating of "outperform" due to its strong half-year results and improved gross margin guidance [1] Group 2 - The bank expects CanSino Biologics (09926) to report adjusted earnings of RMB 23 million in the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, with a rating of "outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "outperform," reflecting confidence in the company's projected 37% year-on-year growth in product revenue [1] - The bank continues to focus on licensing deals for innovative drugs in China, anticipating more subsidies for high-priced innovative drugs, which may drive sales growth for companies like Kintor Pharmaceutical (02171), Fosun Pharma (600196) (02196), WuXi AppTec (02126), and Kerenor Biotech (06990) [2]

Core Viewpoint - The investment bank maintains a cautiously optimistic outlook on the Chinese pharmaceutical industry, noting a significant average increase of 137% in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals and unaffected by upcoming U.S. tariffs [1] Group 1: Market Performance - The biotech sector has recently experienced some pullback due to disappointing sales figures from major companies in the first half of 2025, including Hutchison China MediTech [1] - Concerns have arisen regarding Trump's phased implementation of drug tariffs, which could escalate to 150% within a year and ultimately reach 250% [1] Group 2: Company Recommendations - The bank's top pick is BeiGene (06160), with a target price set at HKD 230 and a rating of "Outperform," citing strong performance in the first half of 2025 and an improved gross margin guidance despite U.S. tariff impacts [1] - CanSino Biologics (09926) is expected to report adjusted earnings of RMB 23 million for the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, also rated "Outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "Outperform," reflecting confidence in the company's projected 37% year-on-year revenue growth [1] Group 3: Focus on Innovative Drugs - The bank continues to pay attention to licensing deals for Chinese innovative drugs, with expectations of increased subsidies for high-priced innovative drugs, which may drive sales growth for companies such as Kintor Pharmaceutical (02171), Fosun Pharma (02196), WuXi AppTec (02126), and Kelun-Biotech (06990) [2]

Macro Highlights - The People's Bank of China reported that as of the end of July 2025, the broad money supply (M2) reached 329.94 trillion yuan, reflecting a year-on-year growth of 8.8% [1] - The narrow money supply (M1) stood at 111.06 trillion yuan, with a year-on-year increase of 5.6% [1] - In the first seven months of 2025, net funds injected amounted to 465.1 billion yuan, with RMB loans increasing by 12.87 trillion yuan and deposits rising by 18.44 trillion yuan [1] - As of the end of July 2025, the total social financing stock was 431.26 trillion yuan, showing a year-on-year growth of 9% [1] Company News - Chipbond Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange [7] - *ST Tianmao intends to voluntarily terminate its listing through a shareholder resolution, with trading suspension starting from the 14th [8] - Jiangfeng Electronics is planning to integrate its flat panel display target material business with Japan's Aifake Corporation [9] - *ST Baoshi's controlling shareholder plans to change to Ningxia Electric Investment Group [10] - Great Wall Military Industry may apply for a trading suspension if its stock price continues to rise [11] Financial Performance - Harbin Electric achieved a net profit of 380 million yuan in the first half of the year, representing a year-on-year increase of 233.08% [12] - Dongfang Precision Engineering reported a net profit of 397 million yuan in the first half, up 142.52% year-on-year [12] - Aiwei Electronics posted a net profit of 157 million yuan in the first half, reflecting a year-on-year growth of 71.09% [12] - Dingyang Technology's net profit for the first half was 76.88 million yuan, marking a year-on-year increase of 31.54% [12] - China Shipbuilding Industry's net profit for the first half was 57.09 million yuan, down 6.61% year-on-year [12] - Youyan Silicon's net profit for the first half was 106 million yuan, down 18.74% year-on-year [12] - Yanzhou Coal's net profit is expected to decrease by approximately 38% year-on-year [12] - Aolaide's net profit is projected to decline by 68.41% to 72.77% year-on-year [12]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the preliminary review results for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, with 534 drugs passing the initial review, indicating a significant step towards a dual catalog mechanism that promotes both basic insurance and innovative commercial insurance [1][2]. Group 1: Drug Catalog Overview - A total of 534 drugs were reviewed, with 310 drugs excluded from the catalog and 224 drugs included. The commercial insurance innovative drug catalog includes 121 drugs, with 12 drugs under non-exclusive agreements still in negotiation [2]. - The NHSA will continue to advance the basic catalog adjustments and the commercial insurance innovative drug catalog, including expert reviews in August-September, price negotiations in September-October, and results announcement in October-November [2]. Group 2: Dual Catalog Mechanism - The dual catalog mechanism establishes a clear division of responsibilities, where the basic medical insurance catalog covers essential clinical drugs, while the commercial insurance innovative catalog focuses on high-value drugs not covered by basic insurance but with significant clinical value [3]. - The framework encourages commercial insurance companies to invest in innovative drug development through various means, such as investment funds, to provide stable long-term funding for innovative drug research [3]. Group 3: Implications for Drug Development - The commercial insurance innovative drug catalog is a crucial step in developing a multi-tiered medication security system, addressing diverse medication needs of the population. It is believed that supplementing commercial insurance on top of basic insurance will facilitate the introduction of high-priced innovative drugs [4]. - Innovative drugs can accumulate real-world data and enhance clinical penetration through commercial insurance applications, thereby increasing their potential market value [4]. Group 4: Investment Recommendations - Companies to watch include BeiGene, Kelun-Biotech, CanSino Biologics, Innovent Biologics, and Zai Lab, along with other relevant companies such as CSPC Pharmaceutical Group, China National Pharmaceutical Group, and Hengrui Medicine [5].

Core Insights - The National Healthcare Security Administration (NHSA) announced the preliminary review results for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, revealing 534 drugs passed the review, with 121 drugs included in the commercial insurance innovative drug catalog [1][2] - This year marks the first implementation of a "dual-track system" for the drug catalog, focusing on basic insurance for essential drugs and providing supplementary coverage for "exclusive new drugs" or "rare disease medications" through commercial insurance [1][2] - The number of drugs passing the preliminary review has significantly increased compared to last year, with the number of drug names outside the catalog rising from 249 in 2024 to 310 [1] Drug Categories and Highlights - Over 98% of the drugs in the announced list are Western medicines, with only two traditional Chinese medicines included [3] - CAR-T therapies, which are at the forefront of cancer treatment, have gained attention, with several priced over 1 million yuan per injection, including products from Fosun Kite, Kintor Pharmaceutical, and Reindeer Biologics [1][2] - Notable entries in the list include innovative drugs from domestic companies, such as Shanghai Xinnian Pharmaceutical's hemophilia B gene therapy and Hengrui Medicine's PD-1 monoclonal antibody [3] Review and Approval Process - Passing the preliminary review does not guarantee inclusion in the basic medical insurance or commercial insurance innovative drug catalog, as further expert evaluations and price negotiations are required [3] - Approximately 80 drug varieties passed the preliminary review for both the basic medical insurance and commercial insurance catalogs, indicating potential for simultaneous negotiations [3]

Core Insights - The article discusses the announcement by the National Medical Insurance Administration regarding the preliminary review of 534 drugs for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, along with 121 drugs included in the commercial insurance innovative drug catalog [1][2]. Group 1: Drug Catalog Adjustments - The 2025 drug catalog adjustments implement a "dual-track system," focusing on basic insurance for essential drugs while providing supplementary coverage for "exclusive new drugs" or "rare disease medications" through the commercial insurance innovative drug catalog [1][2]. - A total of 718 applications were received for the basic medical insurance catalog, with 534 approved, while 141 applications were received for the commercial insurance innovative drug catalog, with 121 approved [1][2]. Group 2: CAR-T Therapies - CAR-T therapies, which are personalized cancer treatments, have gained attention due to their high costs, with prices exceeding 1 million yuan per injection for several products [1][2]. - The article highlights that CAR-T therapies are among the first specialty drugs to be included in commercial insurance coverage, with various regions like Jiangsu and Shanghai incorporating them into their insurance plans [2]. Group 3: Drug Composition and Approval Process - The approved drugs are predominantly Western medicines, with over 98% of the list, and only two traditional Chinese medicines included [3]. - The approval of drugs through preliminary review does not guarantee inclusion in the basic medical insurance or commercial insurance catalogs, as further expert evaluations and price negotiations are required [3]. Group 4: Pricing and Negotiation - Approximately 80 drug varieties passed the preliminary review for both the basic medical insurance and commercial insurance catalogs, indicating potential for simultaneous negotiations [3]. - Drugs that exceed the basic insurance pricing limits may still qualify for the next evaluation stage, but their final inclusion depends on successful negotiations [3].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [3]. Core Insights - The report highlights the significant sales performance of Ansai's Claudin 18.2 monoclonal antibody VYLOY, which achieved sales of 14 billion yen in Q2 2025, exceeding expectations and indicating strong market potential for the Claudin 18.2 target [5][15]. - The report emphasizes the growing interest and investment opportunities in the Claudin 18.2 target, particularly in the context of gastric cancer treatment, where there is a substantial unmet medical need [18][19]. - The report notes that the innovative drug industry is experiencing a resurgence, with increased investment and accelerated research and development activities, benefiting various sectors within the pharmaceutical industry [4][14]. Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector experienced a weekly return of -0.84%, ranking last among 31 sub-industry indices [4][14]. - The medical device sector showed the highest weekly increase at 2.70%, while the medical services sector faced the largest decline at -2.22% [4][14]. 2. Key Developments - Ansai's VYLOY is set to launch in multiple regions, including Japan, Europe, the United States, and China, with a projected global sales figure of 12.2 billion yen for FY2024 [5][15]. - The report identifies several Chinese companies making strides in the Claudin 18.2 space, including CAR-T and ADC therapies, indicating a competitive landscape [5][22]. 3. Investment Opportunities - The report suggests focusing on leading CXO companies with global influence, such as WuXi AppTec and others, as well as domestic clinical CRO leaders [4][14]. - It also highlights the potential for high-end medical device companies to benefit from domestic replacements, recommending companies like Mindray and others [4][14]. 4. Competitive Landscape - The global competitive landscape for the Claudin 18.2 target is characterized by diverse technologies and rapid iterations, with Ansai's monoclonal antibody leading the market [22][23]. - The report notes that approximately 81 out of 98 drugs in development for Claudin 18.2 are led by Chinese companies, showcasing the domestic focus on this therapeutic area [19][22].